The cysteinyl leukotrienes (CysLTs) 
INTRODUCTION

Activation of the leukotriene synthetic pathway occurs in inflammatory or allergic cells following stimulation of intracellular calcium release by specific plasma membrane activating molecules such as bacterial cell wall antigens on neutrophils or IgE on mast cells. 1,2 Calcium release induces the translocation of five-lipoxygenase (5-LO) and cytosolic phospholipase A2 to the nuclear membrane where arachidonic acid is released and presented to 5-LO by fivelipoxygenase-activating protein (FLAP). 3 FLAP is one of the membrane associated proteins of eicosanoid and glutathione metabolism ( MAPEG ) family of which there are six members that are involved in either detoxification or eicosanoid synthesis. It is possible that FLAP evolved from an early evolutionary detoxification role to a specific cofactor for the production of leukotriene A4(LTA4
i g . 1 P o t e n t i a l C y s L T s i g n a l i n g p a t h wa y s i n i n f l a mma t o r y c e l l s i n a l l e r g i c r h i n i t i s . R e p r i n t e d wi t h p e r mi ss i o n f r o m F i g u e r o a DJ e t a l . E x p r e s s i o n o f c y s t e i n y l l e u k o t r i e n e s y n t h e t i c a n d s i g n a l i n g p r o t e i n s i n i n f l a mma t o r y c e l l s i n a c t i v e s e a s o n a l a l l e r g i c r h i n i t i s . C l i n . E x p . A l l e r g y 2 0 0 3 ; 3 3 : 1 3 8 0 -1 3 8 8 .
pressed on 40 60% of neutrophils recovered in nasal secretions from patients suffering from active allergic rhinitis. 10 Figure 1 .
In allergic subjects, CysLTs ( but not LTB4 ) are elevated following specific ragweed allergen challenge in a ragweed pollen dose-dependent fashion. [13] [14] [15] [16] The elevations in CysLTs correlate temporally with the severity of the symptoms of allergic rhinitis. 15 Intranasal challenge with LTD4 results in nasal secretions (rhinorrhea) peaking at 5 minutes after LTD4 challenge and returning to control levels within 20 minutes. 16 In addition, intranasal LTC4 challenge in 5 patients increased nasal airway resistance in a dose-dependent fashion. 13 The severity of nasal blockage in allergic rhinitis is proportional to the nasal eosinophil concentration. 17 33 The increase in superoxide radicals was blocked by treatment with the CysLT1 receptor antagonist pranlukast. 33 As described above CysLT1 receptor antagonists block effects of CysLT activation of eosinophils, mast cells and neutrophils. Pranlukast has been shown to be effective in the prevention of LTD4-induced nasal secretion, nasal airway resistance and nasal eosinophil infiltration in a guinea pig model of allergic rhinitis. 34 Pranlukast has also been shown cause a significant decrease in eosinophil infiltration and cytokine production in human nasal mucosa of patients with perennial allergic rhinitis. 35 Montelukast at 10 mg once daily dosing has shown efficacy against daytime and nighttime symptoms and improved quality of life scores in multi-center , randomized , double-blind , placebo-controlled seasonal allergic rhinitis trials held in spring and fall. [36] [37] [38] In the spring trial montelukast was also shown to decrease peripheral blood eosinophil counts indicating both nasal and systemic anti-inflammatory effects in this trial. 37 The pathophysiology of rhinitis has many common features with that of asthma and 20 50% of patients with rhinitis also have asthma, whereas 80% or more of patients with asthma have concomitant rhinitis. 39 This has lead to the hypothesis that systemic drugs such as CysLT1 receptor antagonists may treat both upper and lower airway disease treating the inflammatory one airway' symptoms for patients with both asthma and allergic rhinitis . [40] [41] [42] [43] 
